Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-in-Human, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 Following Single Ascending Dose Administrations to Healthy Male Subjects of African Ancestry

Trial Profile

A Phase I, First-in-Human, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 Following Single Ascending Dose Administrations to Healthy Male Subjects of African Ancestry

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 2373 (Primary)
  • Indications Kidney disorders
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca

Most Recent Events

  • 05 Jan 2023 Status changed from discontinued to completed.
  • 20 Sep 2021 Status changed from active, no longer recruiting to discontinued AZ has decided not to continue this study, since sufficient data are available to supportproposed dosing in future studies, and assessment of higher single doses are limited by tolerability due to the development of Injection Site Reactions. .
  • 18 Jun 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top